Oxis Turbohaler (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate, the active ingredient in Oxis Turbohaler, is a long‑acting β2‑adrenergic agonist (LABA) presented as an inhalation device for inhalation use. It provides maintenance bronchodilation for asthma and chronic obstructive pulmonary disease (COPD) in adults. GNH USA supplies Oxis Turbohaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oxis Turbohaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Formoterol fumarate dihydrate is a LABA that acts on the bronchial smooth‑muscle pathway to improve airflow in chronic respiratory disease.

- Asthma: provides long‑term bronchodilation as part of maintenance therapy in adults. - Chronic obstructive pulmonary disease (COPD): improves lung function and reduces symptom variability when used regularly. - Exercise‑induced bronchoconstriction: helps prevent airway narrowing during physical activity in patients with known reactive airway disease.

Formoterol may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Throat irritation: mild discomfort or scratchy feeling in the throat. - Cough: transient coughing after inhalation. - Headache: mild to moderate headache. - Tremor: fine muscle tremor, often of the hands. - Palpitations: sensation of rapid or irregular heartbeat. - Nasal congestion: feeling of a blocked nose.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing difficulty. - Cardiovascular events: arrhythmia, tachycardia, or angina. - Hypokalemia: low blood potassium levels. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Hyperglycaemia: elevated blood glucose in susceptible individuals. - Throat infection: rare occurrence of fungal or bacterial infection in the oropharynx.

When using Oxis Turbohaler, consider the following safety measures:

- Assess asthma control: verify that the patient remains symptomatic despite inhaled corticosteroid therapy. - Review cardiovascular history: check for arrhythmias, hypertension, or ischemic heart disease before initiating therapy. - Monitor for paradoxical bronchospasm: educate patients to seek immediate help if breathing worsens after use. - Avoid abrupt discontinuation: taper if therapy is stopped after long‑term use to reduce rebound bronchoconstriction. - Store at ambient temperature: keep below 25°C, protect from moisture and direct sunlight.

Formoterol may interact with several drug classes that influence cardiovascular or respiratory function.

Major Interactions (Avoid): - Non‑selective β‑blockers: antagonize bronchodilator effect and may precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs): increase risk of severe hypertension.\n- Diuretics (especially loop diuretics): may exacerbate hypokalemia caused by β2‑agonists.

Moderate Interactions (Potential: -      ").